Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of KP-001 with Rosuvastatin, Caffeine, and Fluvoxamine
NCT06821698Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KP001 in vascular malformations (VM) (3 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity and Maximum Plasma Concentration. Started Feb 2025; status: completed.
02
Drugs
KP001
03
Conditions
vascular malformations (VM)
Beyond the preview
Go deeper on NCT06821698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821698.